Share this article
Share this article HANGZHOU, China and SAN FRANCISCO, July 11, 2021 /PRNewswire/ Hangzhou Sciwind Biosciences Co., Ltd., a clinical-stage, fast-growing biopharmaceutical company focusing on discovering and developing innovative therapies to treat chronic, metabolic and immunological diseases, announced today the appointment of Dr. Weidong Zhong, former co-founder and executive of Terns Pharmaceuticals, as Chief Strategy Officer and President of its US subsidiary, Sciwind Biosciences USA. Dr. Zhong is a highly accomplished industry leader with an extensive track record in discovering and developing innovative therapies to treat infectious and metabolic diseases, said Hai Pan, Ph.D., founder and CEO of Sciwind. His knowledge and expertise will be very valuable to Sciwind as we advance our differentiated product pipeline through development in China as well as in other global markets. We are thrilled to have Dr. Zhong join us at this critical time in our comp
PSI: Tell me about your background, your areas of expertise and your professional journey.
TM: I am from and grew up in Zimbabwe. I went to Smith College in Massachusetts before going to Harvard Medical School, all at a time when the HIV epidemic was starting to have a significant impact globally and even more so here in Zimbabwe. Halfway through medical school, and after experiencing a family loss, I decided that I wanted to work on fixing the problem. I was determined that I was going to make a vaccine for HIV and that it would end the epidemic.